Jamie Cesanek | Authors


Second-Line Regorafenib/Nivolumab Is Deemed Safe for HCC

March 23, 2022

For patients with hepatocellular carcinoma treated in the second-line setting, the combination of regorafenib and nivolumab following 2 cycles of regorafenib monotherapy appeared safe, according to phase 1/2a study.

Viral Etiology, NLR Lead to Better Responses With Atezolizumab/Bevacizumab Combo in HCC

March 23, 2022

Treatment with atezolizumab plus bevacizumab in the first-line setting achieved better responses for patients with unrespectable hepatocellular carcinoma when their disease had a viral versus nonviral etiology and neutrophil-to-lymphocyte ratio was less than 3.6.

QoL in Patients With Early Breast Cancer May be Impacted by SLNB and ALND

December 16, 2021

Findings from the INSEMA study show that patients who received either sentinel lymph node biopsy or complete axillary lymph node dissection experienced differences in breast and arm symptoms compared with patients who did not.

Ibrutinib/Rituximab Improves Quality of Life as Frontline and Continuous Therapy in CLL

December 12, 2021

Frontline ibrutinib and rituximab plus fludarabine, cyclophosphamide, and rituximab improved quality of life in patients with chronic lymphocytic leukemia; ibrutinib given continuously maintained the improved quality of life, and it did not decline over time.